TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05371054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vysis LSI MYC Break Apart Rearrangement Probe Kit
Description: MYC rearrangement FISH testing is performed using the Vysis LSI MYC Break Apart Rearrangement Probe (Abbott Molecular, Inc.) in the Chromosome Pathology Section, Laboratory of Pathology, CCR, NCI. This kit is not FDA approved. It is being used as a treatment determining in-vitro diagnostic device in this study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vysis LSI MYC Break Apart Rearrangement Probe Kit
Description: MYC rearrangement FISH testing is performed using the Vysis LSI MYC Break Apart Rearrangement Probe (Abbott Molecular, Inc.) in the Chromosome Pathology Section, Laboratory of Pathology, CCR, NCI. This kit is not FDA approved. It is being used as a treatment determining in-vitro diagnostic device in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: administered orally, days 1-10, per specified dose level; every 21 days for up to 12 cycles, or until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: administered orally, days 1-10, per specified dose level; every 21 days for up to 12 cycles, or until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIP152
Description: administered intravenously, days 2 and 9, per specified dose level; every 21 days for up to 12 cycles, or until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIP152
Description: administered intravenously, days 2 and 9, per specified dose level; every 21 days for up to 12 cycles, or until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: administered orally, days 1-10, at a dose of 100 mg; every 21 days for up to 12 cycles, or until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: administered orally, days 1-10, at a dose of 100 mg; every 21 days for up to 12 cycles, or until disease progression or unacceptable toxicity
Study: NCT05899452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bubble blowing (active)
Description: Bubble blowing as a method of active distraction during painful procedure (insertion of an IV cannula)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video distraction (passive)
Description: Video on a tablet computer as a method of passive distraction during painful procedure (insertion of an IV cannula)
Study: NCT05961332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectralis FAF imaging
Description: Spectralis is a scanning laser ophthalmoscope which uses a blue light excitation wavelength of 488nm and a 500nm barrier filter to produce FAF images. Spectralis images 20-55 degrees of the retina.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optos imaging
Description: Optos is an ultrawide field imaging platform which images up to 200 degrees of the retina. It uses both a green-light excitation wavelength of 532nm and a red-light excitation wavelength of 633nm with an emission filter of greater than 540nm to produce FAF images.
Study: NCT05259956

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Schroth based scoliosis specific exercise
Description: The intervention is set to be delivered in a one-hour Schroth-based exercise session, with the frequency of twice a week for five weeks. The exercise consists of active auto-correction in 3D, stabilizing the corrected posture, and training in ADL.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 plus 1 multidimensional exercise therapy
Description: The intervention is set to be delivered in a 90-minute exercise session, with a frequency of twice a week for five weeks. The exercise consists of a one-hour Schroth-based exercise session and an additional 30-minute manipulative therapy of pelvic asymmetry.
Study: NCT05961332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeiss Clarus 700 imaging
Description: Zeiss Clarus 700 is an ultrawide field imaging system with similar retinal coverage to that of Optos. It uses Broad Line Fundus Imaging to produce blue FAF images at excitation wavelengths of 435-500nm and green FAF images at wavelengths of 500-585nm
Study: NCT05710640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tcVNS or Sham tcVNS
Description: tcVNS is administered with a study device that gives off mild electrical impulses through the skin to stimulate the vagus nerve (a nerve that travels underneath the skin in your neck and head). This stimulation triggers a chemical response through the nerves and has been found to be effective in reducing pain and inflammation in several diseases.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tcVNS
Description: tcVNS is administered with a study device that gives off mild electrical impulses through the skin to stimulate the vagus nerve (a nerve that travels underneath the skin in your neck and head). This stimulation triggers a chemical response through the nerves and has been found to be effective in reducing pain and inflammation in several diseases.
Study: NCT06051448

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Promoting Resilience in Stress Management (PRISM)
Description: This program teaches the four pillars of resilience (stress management, goal setting, cognitive restructuring, and benefit-finding) in a one-on-one training program consisting of four 20-30 minute sessions occurring once weekly.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical-focused narrative (CFN)
Description: This program consists of questions posed to adults with primary mitochondrial disease at regular mitochondrial medicine center visits. Specific topics will be discussed at each session. This consists four 20-30 minute sessions occurring once weekly.
Study: NCT06448013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Given by PO
Study: NCT05780710

Intervention type: OTHER
Group type: OTHER
Intervention: Aktiia Optical Blood Pressure Monitoring (OBPM) device and antihypertensive drugs (monotherapy and bitherapy)
Description: The device under test is Aktiia Optical Blood Pressure Monitoring (OBPM) device and the comparator is the Aktiia cuff.~For study GROUP 1:~Study drugs are:~* Perindopril MEPHA (Angiotensin Converting Enzyme (ACE) inhibitors).~* Indapamide MEPHA (Diuretics).~* Amlodipine MEPHA (Calcium channel blockers). In each study treatment period, subjects in GROUP 1 will receive one of the following for each treatment period: monotherapy with Indapamide, bitherapy with Indapamide plus Perindopril, or bitherapy with Perindopril plus Amlodipine.

Intervention type: OTHER
Group type: OTHER
Intervention: Aktiia Optical Blood Pressure Monitoring (OBPM) device and antihypertensive drugs (monotherapy)
Description: Study drugs:~* Perindopril MEPHA (Angiotensin Converting Enzyme (ACE) inhibitors).~* Indapamide MEPHA (Diuretics).~* Amlodipine MEPHA (Calcium channel blockers). In each study treatment period, subjects in GROUP 2 will receive one of the following monotherapies: Perindopril , Indapamide, or Amlodipine.

Intervention type: OTHER
Group type: OTHER
Intervention: Aktiia Optical Blood Pressure Monitoring (OBPM) device and individualized antihypertensive treatment
Description: For study GROUP 3:~Subjects will be prescribed an individualized new antihypertensive treatment at their consultation with the Investigator at Visit 1.
Study: NCT05276180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm A) Multifactorial intervention strategy
Description: Implementation of the multifactorial intervention strategy will be supported by the following components:~1) An implementation team at each intervention unit consisting of 5-6 HCWs is responsible for informing and engaging all HCWs at the unit. For implementing the various components of the strategy. They will have the role of planning regular workplace meetings. 2) One or two internal facilitators will be the link between the external facilitator and the care unit. The internal facilitator will give support with material, information and will be able to ask questions of the external facilitator.~3) External facilitator will ensure that the implementation process works according to plan. The research team will present the results of SMET to the implementation team.~4) The research group will be project leaders and support the external facilitators. They will provide workshops and will also be responsible for data collection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm B) Single intervention strategy
Description: No further interventions other than access to the Swedish guideline for patient handling and movement and the results from the SMET questionnaire will be presented to the manager. Arm B will be assigned an external facilitator who provides information, is present at the start-up meeting and will be the contact person during the study period. No further support will be given to the care units in arm B.
Study: NCT05780931

Intervention type: BEHAVIORAL
Intervention: Study-specific rehabilitation (SSR) procedures
Description: Study-specific rehabilitation procedures will systematically manipulated the spatial or temporal synchrony (or coordination) of visual vs. haptic inputs that the subjects receive.
Study: NCT06511895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4205
Description: AZD4205 capsules administered at 150 mg or 75 mg orally, once daily, in 28-day cycle.
Study: NCT05941559

Intervention type: OTHER
Group type: OTHER
Intervention: EMDR
Description: Eye Movement Desensitization and Reprocessing

Intervention type: OTHER
Group type: OTHER
Intervention: EMDR
Description: Eye Movement Desensitization and Reprocessing

Intervention type: OTHER
Group type: OTHER
Intervention: EMDR
Description: Eye Movement Desensitization and Reprocessing
Study: NCT05650242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA1106
Description: In part A, after the observation period of DLT (28 days), intravenous (IV) once every 3 weeks (Q3W).~In Part B, intravenous (IV) once every 3 weeks (Q3W) or once every 2 weeks (Q2W).
Study: NCT06197347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based nursing intervention : Ch@ngeons Ensemble
Description: The web-based nursing intervention, named Ch@ngeons Ensemble, was designed to increase physical activity and quality of life among older adults living with CHD. The intervention will be multicomponent, including educational content, videos, forums, goal planning, an electronic physical activity journal, and virtual written interactions with a nurse. An initial in-person meeting with the nurse will be provided to foster the older adult's commitment to the intervention and help build a relationship of trust. Throughout the intervention, the nurse will asynchronously provide counseling, feedback, and encouragement, and attempt to promote quality of life, knowledge, motivation, and self-efficacy among the older adults.
Study: NCT05320809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3D189
Description: 3D189 (200 mcg per peptide x 4 WT1 peptides within the drug product; total weight: 800 mcg) is mixed (1:1 v/v) and emulsified with the adjuvant Montanide, which is then injected subcutaneously to the patient.~A maximum of 15 total injections of 3D189 will be administered as follows:~1. Initial immunization induction phase（the first series of 6 injections of 3D189): every 2 weeks (Weeks 0 - 10) followed by a 4-week period of no treatment.~2. Early immune booster phase（the second series of 6 injections of 3D189): every 4 weeks (between Weeks 14 and 34) followed by a 6-week period of no treatment.~3. Late immune booster phase（the third series of 3 injections of 3D189): every 6 weeks (between Weeks 40 and 52).
Study: NCT06176794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate release torsemide 20mg tablet
Description: Subjects will receive approximately one week of daily immediate release 20mg torsemide (plus daily placebo of 24mg extended release torsemide) and one week of daily extended release 24mg torsemide (plus daily placebo of 20mg immediate release torsemide) with no gap in between. Subjects will be randomly assigned to immediate-release torsemide-first arm versus extended-release torsemide-first arm and at the end of the initial one-week period, they will be switched to the other intervention. Subjects will consume only the provided meals with standardized amount of sodium content throughout the study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate release torsemide 20mg tablet
Description: Subjects will receive approximately one week of daily immediate release 20mg torsemide (plus daily placebo of 24mg extended release torsemide) and one week of daily extended release 24mg torsemide (plus daily placebo of 20mg immediate release torsemide) with no gap in between. Subjects will be randomly assigned to immediate-release torsemide-first arm versus extended-release torsemide-first arm and at the end of the initial one-week period, they will be switched to the other intervention. Subjects will consume only the provided meals with standardized amount of sodium content throughout the study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release torsemide 24mg tablet
Description: Subjects will receive approximately one week of daily immediate release 20mg torsemide (plus daily placebo of 24mg extended release torsemide) and one week of daily extended release 24mg torsemide (plus daily placebo of 20mg immediate release torsemide) with no gap in between. Subjects will be randomly assigned to immediate-release torsemide-first arm versus extended-release torsemide-first arm and at the end of the initial one-week period, they will be switched to the other intervention. Subjects will consume only the provided meals with standardized amount of sodium content throughout the study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended release torsemide 24mg tablet
Description: Subjects will receive approximately one week of daily immediate release 20mg torsemide (plus daily placebo of 24mg extended release torsemide) and one week of daily extended release 24mg torsemide (plus daily placebo of 20mg immediate release torsemide) with no gap in between. Subjects will be randomly assigned to immediate-release torsemide-first arm versus extended-release torsemide-first arm and at the end of the initial one-week period, they will be switched to the other intervention. Subjects will consume only the provided meals with standardized amount of sodium content throughout the study period.
Study: NCT05684939

Intervention type: BEHAVIORAL
Intervention: Questionnaire (patient reported outcome)
Description: Online self-administered questionnaire exploring substance use, pain, chemotherapy-induced peripheral neuropathy, health-related quality of life, anxiety, depression, social and material deprivation, patients and oncological charactericitcs, and intercurrent pathologies
Study: NCT06548165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable
Description: Participants will wear an electrode on the chest for the measurement of the heart rate variability, a sensor for temperature measurement, and a sensor for continuous blood glucose measurement. Food intake will be recorded via pictures. One mixed meal tolerance test will be performed as a reference for further analyses. Females have the option to use a device for intravaginal temperature measurement.
Study: NCT06127121

Intervention type: BEHAVIORAL
Intervention: Digital Art Activity
Description: * complete a symptom questionnaire~* complete another activity such as listening to meditative music for 10 minutes~* fill out the symptom questionnaire and engage in the digital art activity again
Study: NCT06503471

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: human umbilical cord mesenchymal stem cell complex collagen
Description: 1 \* 10\^7 cells (2ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cell complex collagen
Description: 1 \* 10\^7 cells (2ml)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrauterine injection
Description: intrauterine injection with human umbilical cord mesenchymal stem cell (19#iSCLife®-UT); total 1 time
Study: NCT06648681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg
Description: The intervention is the oral administration of a study drug containing lemborexant 5 mg daily between 2000h and 0000h for the first 7 days following extubating/initiation criteria is met or until their hospital discharge or until the first diagnosis of delirium, whichever occurs first.~Initiation criteria:~I. The participant has been extubated for at least 2 hours II. all other sedative medications have been discontinued for \>1 hour III. the participant has a Richmond Agitation and Sedation Scale (RASS) score of \>-1 or a Pasero Opioid-induced Sedation Scale (POSS) score \<3.~If satisfactory sleep is not achieved with the 5 mg dose of the study drug, within 1 hour, another insomnia medication may be administered.~IV. The attending physician agrees that the drug can be safely started.~The medication will be held if the patient has been re-intubated, or upon clinical judgement by attending physician.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control (placebo) group
Description: The control group will receive an oral placebo tablet daily between 2000h and 0000h for the first 7 days following extubating/initiation criteria is met or until their hospital discharge, whichever occurs first. The initiation criteria and the procedure if sleep is not initiated within 1 hour is the same as the intervention arm .
Study: NCT05542186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Biomechanical correction for discogenic low back pain using kinesiotaping
Study: NCT04263363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 100 MG/ML [Bridion]
Description: Sugammadex administered to patients within the clinical best practice pathway.
Study: NCT04734782

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of antibodies in maternal serum IgG for respiratory syncytial virus
Description: By venipuncture, a blood sample will be taken and the levels of anti-RSV IgG antibodies will be processed in serum by commercial techniques.

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of antibodies in maternal serum IgG for respiratory syncytial virus
Description: By venipuncture, a blood sample will be taken and the levels of anti-RSV IgG antibodies will be processed in serum by commercial techniques.
Study: NCT05820919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LOCK Sleep Program
Description: The LOCK sleep program is a program that trains NH staff in a NH frontline staff huddling approach. It is derived from evidence supporting strengths-based learning, systematic observation, relationship-based teamwork, and efficiency. Staff learn how to work together as a team to collaboratively problem-solving about resident sleep challenges (e.g., evidence-based sleep promoting best practices and daytime meaningful activity best practices).

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention (control period/baseline data collection)
Description: Each NH serves as its own control. During the control period, baseline data will be collected.
Study: NCT05901116

Intervention type: OTHER
Group type: OTHER
Intervention: Serratus posterior superior intercostal plane block (SPSIPB)
Description: Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
Study: NCT05391958

Intervention type: GENETIC
Group type: SHAM_COMPARATOR
Intervention: obese patients
Description: obese patients with elective laparoscopic colorectal surgery were selected，and the inclusion criteria were as follows: age 18-65, body mass index (BMI) 30-35, waist circumference (WC) : female ≥80cm, male ≥90cm, and American Society of Anesthesiologists (ASA) grade Ⅰ \~ Ⅲ.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: normal patients
Description: normal patients with elective laparoscopic colorectal surgery whose body mass index (BMI) 18-24 were selected,and American Society of Anesthesiologists (ASA) grade Ⅰ \~ Ⅲ.
Study: NCT05159908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-921352
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-921352
Description: Tablets for oral administration
Study: NCT05391958

Intervention type: GENETIC
Group type: SHAM_COMPARATOR
Intervention: normal patients
Description: normal patients with elective laparoscopic colorectal surgery whose body mass index (BMI) 18-24 were selected,and American Society of Anesthesiologists (ASA) grade Ⅰ \~ Ⅲ.
Study: NCT05159908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-921352
Description: Tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets for oral administration
Study: NCT06293963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline Daily Amounts label
Description: Labels that list the amount and percent of daily value of added sugar, sodium, or saturated fat, modeled after Guideline Daily Amounts labels.
Study: NCT04798820

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary education(nutritional counselling)
Description: Dietary education provided to gastrectomy patients by dietitian.
Study: NCT06293963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretive text-only label
Description: Interpretive text-only labels that state when a product contains high amounts of added sugar, sodium, or saturated fat.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretive magnifying glass icon label
Description: Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Separated interpretive magnifying glass icon label
Description: Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon. Each nutrient will be on a separate label.